J&J CEO Joaquin Duato on Obesity, Cancer and AI | The David Rubenstein Show
Johnson & Johnson CEO Joaquin Duato says the company has no plans to enter the obesity market, instead focusing on areas such as cancer. He says oncology remains one of J&J's core growth pillars, and highlights dementia as another major challenge for the healthcare industry. Duato also talked about how artificial intelligence could accelerate drug discovery and the development of new medicines.…
We haven't written up this one. Bloomberg has the full story — the link below goes straight to it.
